Loading…
Loading…
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the preclinical translational package supporting Sapu003, the Company's intravenous Deciparticle™ formulation of everolimus. The publication provides a complete evaluation of the formulation's absorption, distribution, metabolism, excretion (ADME), pharmacokinetics (PK), tissue distribution, GLP toxicology, and cGMP manufacturing, representing one of the most comprehensive nonclinical evaluations reported for an intravenous formulation of everolimus.
AGOURA HILLS, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the preclinical translational package supporting Sapu003, the Company's intravenous Deciparticle formulation of everolimus.
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle Platform SAN DIEGO, Calif. , July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB: OTLC), an AI/Robotic native biotechnology company, and its 45% owned subsidiary- Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticle nanomedicine platform, and today announced that the independent Safety Review Committee (SRC) has completed its review of the initial safety cohort in the Company's ongoing SP-03-B101 Phase 1b clinical trial evaluating Sapu003, an investigational intravenous formulation of everolimus.
Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle ™ Technology for Hydrophobic Therapeutics
Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the launch of its artificial intelligence ("AI") powered good manufacturing practices ("GMP") manufacturing services platform (the "Platform") at the 2026 BIO International Convention in San Diego, California.
SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint manufacturing automation initiative with TechForce Robotics, Inc. ("TechForce"), advancing the commercialization of an artificial intelligence ("AI") powered good manufacturing practices ("GMP") manufacturing services platform (the "Platform") at SAPU Bio, Oncotelic's 45%-owned OEB-5 sterile injectable cGMP manufacturing joint venture.